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Abstract   37 
Background: 38 
 39 
Inclusion health focuses on people in extremes of poor health due to poverty, 40 
marginalisation and multiple morbidity. We aimed to synthesise morbidity and 41 
mortality data on overlapping populations experiencing deep social exclusion evident 42 
by homelessness, substance use disorders, sex work and imprisonment. 43 
 44 
Methods:  45 
 46 
We searched Medline, Embase and the Cochrane Library for studies published 47 
January 2005-October 2015. We included articles written in English from high-48 
income countries that were conducted in populations with histories of homelessness, 49 
imprisonment, sex work and substance use disorder (excluding cannabis and 50 
alcohol). Primary outcomes were measures of morbidity (prevalence or incidence) 51 
and mortality (standardised mortality rates – SMRs – and mortality rates). 52 
 53 
Findings:  54 
 55 
Our search identified 7946 articles, with 337 studies included. All-cause SMRs were 56 
significantly raised in 98.9% (91/92) of extracted data points and were 11.9 (95% CI 57 
10.4–13.3; I2 94,1%) in females and 7.9 (95% CI 7.0–8.7; I2 99.1%) in males. 58 
Heterogeneity was high between studies. Summary SMR estimates for ICD-10 59 
categories with two or more included data points were highest in deaths due to injury 60 
and poisoning in males (7.9; 95% CI 6.4-9.4; I2 98.1%) and females (18.7; 95% CI 61 
13.7-23.7; I2 91.5%). Disease prevalence was consistently raised across infections, 62 
mental health, neoplasms, cardiovascular, gastroenterological and respiratory 63 
conditions. 64 
 65 
Interpretation: 66 
 67 
Socially excluded populations experience extreme health inequalitiesinequities,; far 68 
greater than those observed amongst people living in areas of high social 69 
deprivation. These inequalities inequities occur across the full spectrum of health 70 
conditions, with the relative impact of exclusion being greater in females than males. 71 
Measures of morbidity and mortality were much higher than those observed across 72 
area based measures of social deprivation highlighting the need for better data on 73 
these populations who are largely invisible in routine health information systems. The 74 
extreme health inequity demonstrated demands intensive cross sectoral policy and 75 
service action to prevent exclusion and improve health outcomes in those already 76 
marginalised. 77 
 78 
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  84 
Introduction  85 
 86 
Inclusion health is a research, service, and policy agenda that aims to prevent and 87 
redress health and social inequities among people in extremes of poor health due to 88 
poverty, marginalisation and multiple morbidity (cross reference IH paper 2). It is well 89 
established that in high income countries, health outcomes are strongly influenced 90 
by socioeconomic statusThe association between socioeconomic status and health 91 
outcomes is well established.  For example, the standardised mortality rates for 92 
those aged 15–64 in the most deprived twentieth of areas neighbourhoods of in 93 
England are is 2.8 times the rate in the least deprived areas neighbourhoods for men 94 
and 2.1 times the rate for women.1  However, analyses based on geographical 95 
location may obscurethese commonly observed social gradients in health may not 96 
capture the true full extent of health inequities in for those who experiencinge deep 97 
social exclusion. 1 98 
 99 
Previous research has described the high levels of substance use disorders (SUD) in 100 
homeless populations2, prisoners3, and sex workers4, and the increased prevalence 101 
of homelessness in prisoners5 and sex workers6. These marginalised populations 102 
have common intersecting characteristics and adverse life experiences that lead to 103 
deep social exclusion, making them some of the most commonpowerful 104 
determinants of marginalisation in high-income settings.7  105 
 106 
Marginalised populations when considered separately have been shown to have 107 
high levels of all-cause mortality.8–10 However, despite the highly overlapping nature 108 
of the risk factors and substantially increased mortality, no previous review has 109 
attempted to examine their outcomes together.  110 
 111 
No universally agreed theoretical framework describes inclusion health. However, 112 
wWe build on existing social exclusion theory and consider the “‘linked and 113 
cumulative factors’” and processes that confound individual and group capacity for 114 
hope, opportunity, reciprocity and participation”.’.11 Our analysis is also informed by 115 
an intersectionality perspective, which focuses on how social characteristics combine 116 
to impact on health.2,12  117 
 118 
Our systematic review examines the health outcomesmortality and morbidity in four 119 
overlapping populations together as exemplar determinants of deep exclusion:. We 120 
aimed to systematically review and meta-analyse mortality and morbidity in 121 
homeless, prison, sex work, and SUD populations jointly for the first time. 122 
Methods 123 
We searched the Cochrane Library, Medline and Embase from 1 January 2005 and 124 
to 1 October 2015 on 27 October 2015. Full search terms are provided in the 125 
supplementary appendix. We searched for papers about the populations of interest 126 
(homeless, prison, sex workers and SUD) from systematic reviews, meta-analyses, 127 
interventional and observational studies with morbidity and mortality outcomes. We 128 
included studies identified from references of included articles.  129 
 130 
We recognise that social exclusion has a major impact on health in other groups, 131 
such as Gypsies and Travellers and vulnerable migrants, ethic minorities, indigenous 132 
communities and sexual and gender minorities, most notably transgender populations. Whilst these groups experience 133 
social exclusion in many high-income settings, they were considered beyond the 134 
scope of this review.  135 
 136 
RWA screened titles, abstracts and full texts using Covidence systematic review 137 
software (https://www.covidence.org/). All authors contributed to data extraction 138 
(conducted using a Google Docs https://docs.google.com/) and data were double-139 
checked by a second researcher (RWA, ET, GH or SVK). Extracted items included 140 
study design, year(s) of study, country, number of participants, primary outcome(s), 141 
and summary description of the study population. We attempted to contact authors if 142 
we were unable to locate papers, or required additional information about the data or 143 
study.  144 
 145 
We attempted to identify and exclude duplicate data from research studies presented 146 
in separate publications. Where we identified multiple studies with duplicated or 147 
overlapping data (by population, time, place and outcome) we chose the study with 148 
the largest or most representative sample size, and when these were also similar, 149 
we present the most recent study. We followed the PRISMA reporting guidelines in 150 
the presentation of our manuscript. A review protocol was not published prior to 151 
conducting the review.  152 
 153 
Outcomes 154 
 155 
Outcomes included were measures of morbidity and mortality for ICD-10 defined 156 
conditions. Papers use a variety of measures to report outcomes.  In order to ensure 157 
maximum comparability across studies for mortality outcomes, we extracted, in order 158 
of preference the first of:  the first reported measure out of the following: SMRs,; 159 
relative hazard ratio,; mortality rate ratio,; or crude mortality rate. For consistency 160 
with the majority of studies included in the review, we have not multiplied SMRs by 161 
100. In our results a value of 1 equates to no difference between the expected and 162 
observed mortality rate. For morbidity outcomes, we extracted, in order of preference 163 
the first of: prevalence,; incidence,; prevalence risk ratio (PRR),; incidence rate ratio 164 
(IRR),; prevalence odds ratio (POR),; or incidence odds ratio (IOR). Where available, 165 
we used data where the comparison group was selected as a socially deprived 166 
population or measures adjusted for area-based or income-based deprivation. 167 
 168 
Statistical analysis 169 
 170 
We include all extracted data in an online supplementary appendix. For the 171 
quantitative findings analysed in the paper we focus the synthesis on the primary 172 
outcome of SMRs. SMRs for all-cause mortality and by ICD-10 chapter were 173 
summarised in forest plots. We anticipated high levels of heterogeneity a-priori, and 174 
therefore created summary estimates using random effects models using Stata v.13 175 
(Statacorp LP, College Station, TX, USA). We used the I2 transformation to describe 176 
the proportion of total variation in study estimates due to heterogeneity.14 We 177 
explored potential sources of heterogeneity by stratifying the analyses by country 178 
and by inclusion health population group. We describe the results of studies of 179 
disease prevalence individually.We report summary estimates of morbidity and 180 
mortality of recently published meta-analyses found by our search within our results 181 
and did not attempt to update each of these within our review. In addition to our 182 
quantiative synthesis of data, we present results from exemplar studies for a wider ange of mortality and morbidity outcomes included in the analysis to highlight key themes and issues identifed by the review.   183 
 184 
Role of the funding source 185 
 186 
The study sponsors had no role in study design; in the collection, analysis, and 187 
interpretation of data; in the writing of the report; and in the decision to submit the 188 
paper for publication. All authors had access to all the data, and were responsible for 189 
the decision to submit the manuscript. 190 
Results 191 
We A search of the bibliographic databases was conducted on 27th October 2015 192 
and identified 7,946 articles with 1,274 duplicate articles then excluded (Figure 1). Of 193 
the 711 full text articles retrieved, 418 met the inclusion criteria., but a We excluded 194 
a further 81 were  excluded due to overlapping data. A total of 337 studies were 195 
included in the review, with including 3,219 ‘data points’ (meaning an resulteffect 196 
estimate for a unique population) extracted and 2,835 included after removal of 197 
duplicates.  198 
 199 
The included studies presented data from 38 out of 80 high-income countries (Figure 200 
2)studies were from 38 countries (See Figure S1 in supplementary appendix). USA 201 
(698 data points), Australia (460), Sweden (309), Canada (257), and United 202 
Kingdom (234) were the five countries withhad the highest number ofmost datadata 203 
points (number in brackets for each) included in the review after de-duplication. SUD 204 
populations were the most studied sub-group groups, accounting for  contributing to 205 
42.1% (1,192/2,835) of all data points (after de-duplication), followed by prisoners 206 
(27.1%; 769/2,835), homeless (26.6%; 754/2,835) and sex workers (4.2%; 207 
119/2,835).  208 
 209 
Infectious diseases and mental and behavioural disorders were the two most studied 210 
ICD-10 chapters with a total of 897 (31.6%; 897/2,835) and 715 (25.2%; 715/2,835) 211 
included data points respectively (Figure 32). Injury and poisoning only contributed 212 
3.4% (98/2,835) of all extracted data points.  213 
Our meta-analyses focused on SMRs {(Tables 1 and 2 and Figures 3, 4, and 5)}. 214 
The most studied causes of death were ‘all-cause’ {(XX% of data points)} and ‘injury, 215 
poisoning and external causes’ {(XX% of data points)}. Most studies in the meta-216 
analysis were of SUD groups, including {XX% (XX/XX)} studies of all-cause 217 
mortality. Cause-specific studies in males and females were split between prisoners 218 
and SUD groups, while cause-specific studies for both sexes combined were in SUD 219 
groups only. There were only {three} studies of homeless people included in the 220 
meta-analysis and none of FSW. 221 
Our all-cause meta-analyses focused on SMRs, with 31 studies10 contributing 92 222 
data points (Table 1 & Figures 3, 4 & 5). 98.9% (91/92) of all included all-cause 223 
SMRs were increased and overall we estimated that summary all-cause SMRs were 224 
higher in females 11.9 (95% CI 10.4–13.3; I2 94.1%) than males 7.9 (95% CI 7.0–225 
8.7; I2 99.1%). We provide summary estimates of SMRs, however, data were 226 
heterogeneous as measured by the I2 statistic in many of our analyses (which we 227 
have explored further and therefore these summary measures must be interpreted 228 
with appropriate caution. Heterogeneity was not substantially reduced when 229 
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analyses by population subgroup were undertaken. Insufficient data were available 230 
to conduct subgroup analyses by country.  231 
 232 
Summary SMRs were higher in females than in males for all-cause mortality and 233 
mortality in each of the ICD-10 chapters. In some ICD-10 chapters, the summary 234 
SMR for both sexes combined did not fall between the male and female estimates. 235 
This is because the meta-analyses draw on different studies (rather than the 236 
estimate for both sexes combined being drawn from the samemale and female 237 
populations).  238 
 239 
 240 
Infectious and parasitic diseases were the most studied disease conditions in 241 
inclusion health populations and we identified 201 papers contributing to 31.6% 242 
(897/2,835) of all data extracted (Table 2). Summary estimates of SMRs for 243 
infectious diseases were raised for males (2.8; 95% CI 1.6-4.1; I2 65.4%) and 244 
females (5.6; 95% CI 1.5-9.7; I2 60.0%). Disease prevalence was high but 245 
heterogeneous. HIV ranged from 0%(0/146)15 to 61.5% (44/69)16, Hepatitis C from 246 
0.1% (1/734)17 to 92.8% (64/69)16, Hepatitis B from 1.7% (2/119)18 to 65.0% 247 
(67/103)19, and latent tuberculosis infection from 1.2% (1/82)20 to 50.6% (133/263)21.  248 
 249 
It was estimated that 2.2 million prisoners globally were hepatitis C positive with the 250 
largest populations in North America (668,500).28 A meta-analysis of the prevalence 251 
of sexually transmitted infections (STIs) in prisoners found marked wide variation 252 
and reported a pooled prevalence for Chlamydia of 5.8% (95% CI 5.0-6.5%) in men 253 
and 12.3% (95% CI 10.6-14.0%) in women; gonorrhoea, 1.4% (95% CI 1.1-1.7%) in 254 
men and 5.7% (95% CI 4.8-6.7%) in women; and syphilis, 2.5% (95% CI 2.1-2.8%) 255 
in men and 6.1% (95% CI 4.8-7.5%) in women.29  256 
 257 
 258 
 259 
SMRs for males and females were exclusively from prison populations. SMR data for 260 
both sexes combined were from SUD populations only, with all subgroups by sex 261 
having fewer than three studies included.  262 
Other non-communicable diseases 263 
 264 
Summary estimates of SMRs due to neoplasms were raised in males (1.6; 95% CI 265 
1.3-1.9; I2 88.7%), females (1.9; 95% CI 1.3-2.5; I2 62.8%) and both sexes combined 266 
(2.2; 95% CI 1.6-2.8; I2 90.6%).  267 
In homeless adults in Toronto, 59% had moderate, severe or very severe symptoms 268 
of dyspepsia (around twice as many as in the general population).52 In prisoners in 269 
the USA, 4.9% of male and 9.6% of females had a history of hepatitis and 1.2% of 270 
men and 2.1% of women had a history of cirrhosis.53 A dental survey of inmates in a 271 
juvenile detention facility in Texas showed higher Decayed, Missing or Filled scores 272 
than age and ethnicity matched population controls.54 Dental health problems were 273 
also common in homeless people.55 274 
 275 
 276 
The available body of evidence is largest for infectious diseases, with considerable 277 
existing research on morbidity associated with mental and behavioural disorders. In 278 
contrast, there is a relative paucity of evidence on non-communicable diseases and 279 
injury, poisoning and external causes despite these causes having the highest SMRs 280 
across ICD-10 categories. SMRs across disease categories were consistently higher 281 
in females than males. Of the four inclusion health populations considered, sex 282 
workers were the least well investigated, which should be addressed as a matter of 283 
priority.  284 
 285 
Our study comprehensively describes for the first time the relative mortality and 286 
morbidity burden in selected inclusion health populations. We have synthesised the 287 
significant existing literature in this area using a comprehensive search strategy to 288 
identify the current balance of evidence available to inform policymaking around 289 
inclusion health. Data were extracted and reviewed by a second author reducing the 290 
likelihood of errors. Our approach has allowed us to identify relative gaps in terms of 291 
both categories of disease and inclusion health categories. Our analysis was 292 
informed by an intersectionality perspective, which focuses on how social 293 
characteristics in combination impact on health.7,31 We have therefore specifically 294 
investigated how the health consequences of exclusion may vary by other socially 295 
influenced characteristics, with differences by gender particularly noteworthy. 296 
 297 
A number of limitations should be considered. Caution must be taken when 298 
interpreting the summary estimates of SMRs due to the high level ofthe 299 
heterogeneity foundof studies. A lack of internationally agreed definitions for the 300 
populations considered in this review meansof inclusion health groups  there is 301 
variation in the levels of risk for included studies which is likely to explain some of 302 
this variation. Similarly, comparison groups varied, with some studies comparing to 303 
general population estimates and others to those from socially deprived areasusing 304 
the general population and others using groups living in socially deprived areas.  305 
Studies also varied according to the extent that analyses adjustedof adjustment for 306 
social deprivation and other risk factors. However, wWe have utilised used a 307 
random-effects methods to model the data appropriately and note existing 308 
recommendations that meta-analysis should be pursued whenever possible, with 309 
appropriate acknowledgement of its limitations whenacknowledging heterogeneity is 310 
high.32 We limited our search to 2005 onwards and therefore longer term time trends 311 
are not possible to examine with this analysiswe have not examined longer-term 312 
trends. Furthermore, there is a need for future investigation of how contextual 313 
factors, such as a country’s social policies, influence health outcomes for excluded 314 
groups. Lastly, for pragmatic reasons, we were unable to investigate many other 315 
dimensions of social exclusion. We thereforeother health inclusion groups and 316 
believe that further work is required to investigate the health experiences of other 317 
socially excluded groupsdescribe their health experiences.     318 
 319 
We found consistently higher SMRs for females than males. Since general 320 
population mortality rates are lower in women than men for most conditions this does 321 
not necessarily indicate worse outcomes in women in inclusion health groups 322 
compared with men.  It may however reflect an increased vulnerability of women in 323 
inclusion health populations or different risk distributions among women and men in 324 
inclusion health groups. SMR is a relative measure and the lower SMRs for common 325 
conditions such as cardiovascular disease and cancer may underplay the number of 326 
excess cases. Conversely, high SMRs may not indicate a large number of excess 327 
cases if the condition is rare. Further work should report absolute as well as relative 328 
measures of mortality.  329 
SMR is a relative measure, consequently less extreme SMRs seen for common 330 
conditions such as cardiovascular disease and cancer may underplay the 331 
importance of these outcomes at a population level.  Conversely high SMRs for rare 332 
conditions may inflate their apparent relevance.  Further work should report absolute 333 
as well as relative measures of mortality for different conditions to enable a better 334 
assessment of the contribution of different causes of mortality.  335 
These extreme inequalities inequities demand an intensive cross- sectoral policy and 336 
service response to prevent exclusion and improve health outcomes. An 337 
accompanying review (cross reference IH paper 2) outlines interventions that 338 
respond to these increases in morbidity and mortality. Here we focus on research 339 
recommendations in relation to disease burden measurement to address issues 340 
identified by our review and we briefly discuss the health system response.  341 
 342 
Determining the burden of disease remains challenging in inclusion health 343 
populations as membership of an inclusion health population is not recorded in most 344 
vital registration and health information systems. Deaths and health service usage in 345 
excluded populations are therefore a largely invisible and neglected problem as far 346 
as routine statistics are concerned. By contrast, the availability of area-based 347 
measures of social deprivation across high income countries has allowed 348 
measurement of the major population level impact of less extreme social inequalities.  349 
This has supported extensive cross sectoral policy initiatives to address these 350 
inequalities.33 Better routine data is also needed to drive the policy response to the 351 
inclusion health agenda. 352 
 353 
There are two broad potential approaches to tackling the lack of routine mortality and 354 
health service data for inclusion health groupsthis problem.  Routinely recording 355 
membership of inclusion health groups in health and mortality records is a 356 
possibilityFirstly, health services could routinely record membership of health 357 
inclusion groups. This would require clear agreed definitions of excluded populations 358 
each groupto be agreed along with standard outcome measures. Those responsible 359 
for recording data would need clear guidance to help them ascertain membership of 360 
inclusion health groups and sensitivity would be needed to ensure this does not 361 
reinforceavoid reinforcing of existing stigma for socially excluded groups.34 The 362 
feasibility of routinely recording membership of these inclusion health groupsthis 363 
approach  outside the context of specialist services remains unclear. Alternatively, 364 
and more feasibly in the short term, data linkage methodologies methods could be 365 
used to match data from services that work with excluded populationsinclusion 366 
health groups, with vital registration data, electronic health records, and existing 367 
infectious and non-communicable disease surveillance systems.35 These linked 368 
datasets would then facilitate systematic estimates of mortality and morbidity over 369 
time. This has been the primary method used to estimate SMRs in the studies 370 
reported in this paper. These linked datasets would facilitate systematic estimates of 371 
mortality and morbidity over time and help to measure the impact of 372 
interventions.Routine linkage of such datasets could facilitate systematic estimates 373 
of mortality and morbidity over time and help to measure the impact of policies and 374 
interventions.  375 
 376 
As part of this wider Lancet Series we held an engagement workshop with people 377 
with lived experience of homelessness and social exclusion (described in more detail 378 
in paper 2). We asked this group about their views on collecting operational data with 379 
ethical and appropriate research governance approvals, but without specific 380 
individual level consent. Although this was only a small sample (and we 381 
acknowledge that people who face exclusion and are willing to come in to a 382 
workshop may differ from those who do not) acceptability of collection of this sort of 383 
data was extremely high. 100% of users were happy for homeless hostel records to 384 
be collected, 73% agreeing to the collection of criminal records, 62% to health 385 
records, and 85% agreeing to these records being linked together.  386 
 387 
A vertical approach to tackling inclusion health (i.e. one that focusses on specific 388 
diseases or specific risk groups) can ignore and neglectoverlook multiple morbidity 389 
and the social issues faced by excluded populations.36 This can result in 390 
inefficiencies and missed opportunities for prevention, early diagnosis and 391 
management as well as missed opportunities for mitigation of social risk factors. The 392 
emerging field of inclusion health should advocate for and deliver joined up health 393 
and social services for overlapping marginalised groups. These services should 394 
address not only diseases with extreme disparities, but also prevention and 395 
management of more common conditions with a lower relative risk but high disease 396 
burdenlarge numbers of excess cases, such as cardiovascular disease. The ability of 397 
health and social policy to address the needs of the most marginalised populations 398 
should be a key indicator of quality. Such initiatives need to be supported by robust 399 
information systems that can provide data for continuing advocacy, guide service 400 
development and monitor the health of marginalised populations over time.  401 
 402 
Research in context 403 
 404 
Evidence before this study 405 
There is a comprehensive body of research on the health impact of 406 
inequalityinequity, much of which focusses on disparities in morbidity and mortality, 407 
and is based on area based measures of social deprivationcommon measures of 408 
socioeconomic status such as neighbourhood deprivation and occupational class. 409 
The evidence of a consistent relation between ill health and increasing levels of 410 
social deprivation has underpinned a broad range of social policies and public health 411 
initiatives. Such geographical based analyses cannot adequately assess the extent 412 
of health inequalities inequity experienced by those experiencing deep social 413 
exclusion. In preparation for the inclusion health series we searched the Cochrane 414 
Library, Medline and Embase from 2000 to 30th September 2013. We searched for 415 
systematic reviews, meta-analyses, cohort and cross-sectional studies containing 416 
morbidity and mortality outcomes for the four inclusion health populations of interest 417 
(substance use disorders, homeless populations, prisoners, and sex workers). The 418 
studies identified described the highly overlapping nature of inclusion health 419 
populations, the increased risk factors for disease, and poor mortality outcomes 420 
compared with the general population. 421 
 422 
Added value of this study 423 
Our systematic review and meta-analysis provides the most comprehensive 424 
examination to date of morbidity and mortality outcomes across a range of inclusion 425 
health populations. We find that the extent of the health inequalities inequity seen in 426 
inclusion health populations greatly exceeds that observed when comparing the richest and poorest neighbourhoodshigh 427 
and low socioeconomic groups. Extremely high mortality rates are seen across ICD-428 
10 disease categories, with relative risks consistently higher in females than males. 429 
The relative mortality excess is greatest for injury, poisoning and external causes. 430 
However there is also high, although less extreme, relative mortality inequalities inequity across 431 
more common disease categories such as cardiovascular disease and cancer.  Non-432 
communicable diseases and injury, poisoning and external causes were lacking in 433 
data despite the high summary Standardised Mortality Ratio estimates. Sex workers 434 
were a particularly under-researched group. 435 
 436 
Implications of all the available evidence 437 
The extreme burden of disease experienced by inclusion health populations 438 
demands a cross-sectoral response to prevent deep social exclusion and an 439 
improvement in services working with these populations. This study provides the 440 
most comprehensive assessment to date of the scale and distribution of mortality in 441 
inclusion health populations in high-income countries. Our research focused on 442 
relative measures of mortality and therefore future work should examine absolute 443 
measures in greater detail. Inclusion health populations are often invisible within 444 
routine health data. This limitation can be tackled by either modifying the instruments 445 
used to collect such data or through data linkage studies. Services providing for 446 
inclusion health populations should aim to deliver health and social services for 447 
overlapping marginalised groups, in order to tackle the poor health outcomes found 448 
in this study. These services should also have a greater focus on prevention and 449 
management of more common conditions in addition to those traditionally considered 450 
high risk for inclusion health groups. 451 
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  638 
Tables 639 
 640 
Table 1. Characteristics of studies included in Standardised Mortality Ratio 641 
meta-analyses. 642 
 643 
Author Population Population Description 
Number of 
Participants Country 
Study 
Years 
Nielsen10 Homeless 
Females aged 16yr or more 
with at least one contact with a 
homeless shelter 32711 Denmark 
1999-
2009 
Roy37 Homeless 
Young people aged 14-25 who 
were "street active" 829 Canada 
1995-
2001 
Vila-
Rodriguez38 Homeless 
A prospective community 
sample of adults living in 
single-room occupancy hotel 293 Canada 
2008-
2011 
Graham8 Prisoners 
Males imprisoned for the first 
time between 1996 and 2007 76627 
United 
Kingdom 
1996-
2007 
Kariminia39 Prisoners 
All adults who had experienced 
full-time custody 85203 Australia 
1988-
2002 
Pratt40 Prisoners 
All sentenced and remanded 
prisoners released from prison  244988 
United 
Kingdom 
1999-
2002 
Arendt41 SUD 
People receiving treatment in 
'specialist institutions' for 
substance use disorder, 
reporting  cocaine as their 
primary substance 20581 Denmark 
1996-
2006 
Bargagli42 SUD 
Male opiate users aged 15-69 
entering treatment 2575 
Netherlan
ds 
1996
–
2002 
Barrio43 SUD 
Regular cocaine users 
recruited from drug scenes and 
non-treatment settings 714 Spain 
2004-
2006 
Bjornaas44 SUD 
Individuals with opioid 
addiction hospitalised due to 
self-poisoning 185 Norway 
1980-
2000 
Darke45 I  Opioid users 615 Australia 
2001-
2009 
Degenhardt29 SUD 
Opioid-dependent people 
treated with opoid substitution 
therapy 43789 Australia 
1985
–
2005 
Evans46 SUD 
Young (<30yrs) injecting drug 
users 644 
United 
States 
2005-
2007 
Gibson47 SUD Opioid users 2489 Australia 
1980-
2006 
Hser48 SUD 
Women who were admitted to 
drug-treatment programs 4447 
United 
States 
2000-
2002 
Lee49 SUD 
Heroin users attending for 
opoid substitution therapy 10842 Taiwan 
2006-
2008 
Mathers50 SUD 
People who injected opioids 
and other drugs 101 Denmark 
1980-
1999 
Merrall50 SUD 
People in contact with drug 
treatment services 69456 
United 
Kingdom 
1996-
2006 
Nyhlen51,52 SUD 
Substance abusers admitted 
for inpatient detoxification 561 Sweden 
1970-
2006 
Pavarin53 SUD 
Individuals who had visited a 
public treatment center for 
problems due to the use/abuse 
of cocaine 471 Italy 
1988-
2012 
Rehm54 SUD 
Participants in heroin-assisted 
treatment 6281 
Switzerlan
d 
1994-
2000 
Rosca55 SUD 
Patients who had ever been 
treated or were currently in 
treatment in methadone 
maintainance treatment clinics 9818 Israel 
1999-
2008 
Singleton56 SUD 
Drug users admitted to hospital 
for drug related problems 3039 
Czech 
Republic 
1997-
2002 
Spittal57 SUD 
Injection drug users recruited 
through self-referral and street 
outreach 520 Canada 
1996-
2002 
Stoove58 SUD 
Injection drug users recruited 
through the social networks of 
‘privileged access’ interviewers 220 Australia 
1990-
2006 
van Santen59 SUD 
Individuals from local 
methadone outposts, a 
sexually transmitted diseases 
clinic, and word of mouth. 1254 
Netherlan
ds 
1985-
2012 
Zabransky60 SUD 
Injecting drug users younger 
than nineteen and older than 
fifteen years of age.  151 
Czech 
Republic 
1996-
2008 
Randall61 SUD 
All persons who came into 
contact with the New South 
Wales Opiod Substitution 
therapy program 43789 Australia 
1985-
2005 
Degenhardt62 SUD 
Canadian cohort of daily 
cocaine injectors  717 Canada 
1996-
2004 
Degenhardt63 SUD Opioid users 42676 Australia 
1985-
2006 
 644 
  645 
Table 2. Number of studies and , data points included in the systematic review 646 
and results of meta-analysis of standardised mortality ratios 647 
 648 
ICD-10 chapter Number of 
studies 
Total number of 
data points (% 
of all data 
points) 
Number of 
mortality 
data points 
(% of all 
mortality 
data points) 
Total 337 2835 (100) 336 (100) 
All-cause 32 140 (5) 92 (27)31 
Infectious and parasitic 
diseases 
160 898 (32) 21 (6) 
Neoplasms 4 145 (5) 41 (12) 
Blood  18 (1) -- 
Endocrine  66 (2) 6 (2) 
Mental and behavioural 
disorders 
90 715 (25) 6 (2) 
Nervous system  43 (2) 6 (2) 
Eye and adenexa   14 (0) - 
Ear  4 (0) - 
Diseases of the circulatory 
system 
44 149 (5) 17 (2) 
Respiratory system  79 (3) 8 (2) 
Digestive system  82 (3) 34 (10) 
Skin  44 (2) - 
Musculoskeletal  29 (1)  - 
Injury, , poisoning and certain 
external causes 
 98 (3) 44 (13) 
External causes  207 (7) 61 (18) 
Other     
  649 
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 650 
Figures  651 
 652 
Figure 1. Flowchart of included studies 653 
 654 
 655 
 656 
 657 
Records identified 
through database 
searching from 1 
January 2005 and 1 
October 2015 (n= 7946)
Records screened
(n= 6672)
Records excluded 
duplicates
(n= 1274)
Full text articles 
assessed for eligibility
(n= 711)
Studies meeting 
inclusion criteria
(n= 418)
Studies included in 
quantitative synthesis
(n= 337)
Full text articles excluded
(n= 293)
Excluded because of 
overlapping data with 
other studies
(n= 81)
Articles excluded on title 
and abstract
(n= 5901)
Figure 2. Geographical spread of existing data from high-income countries on homeless populations. 
 
 
 
Included countries: Australia, Austria, Belgium, Canada, Chile, Croatia, Czech Republic, Denmark, Estonia, Finland, France, 
Germany, Greece, Hong Kong, Hungary, Ireland, Israel, Italy, Japan, Latvia, Lithuania, Luxembourg, Netherlands, New Zealand, 
Norway, Poland, Portugal, Puerto Rico, Russia, Singapore, South Korea, Spain, Sweden, Switzerland, Taiwan, United Kingdom, 
United States, Uruguay  
Figure 32. Treemap summarising amount of data by ICD-10 chapter and summary estimates of SMR  
  
 
Note: Size of box indicates number of data points included (e.g. Infectious and parasitic disease = 953; Disease of Nervous system 
= 43). SMR used is summary estimate for ICD-10 chapter for both sexes combined. Boxes without labels are 1=Genitourinary; 
2=Musculoskeletal; 13=symptoms, signs and abnormal clinical and laboratory findings; 42=Ear and Mastoid process; and 53=Eye 
and Adnexa; 4=. Grey boxes (with an SMR of ‘0’) indicate that none of the studies included in this review reported SMR. 
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 Figure 43. Standardised Mortality Ratios for all-cause mortality  
 
 
 
 
Note: Weights are from random effects analysis. Several studies contribute multiple rows of data due to different: SUD groups 
included (Arendt and Pavarin); countries (Bargagli); or time periods (Merrall). 
  
Figure 54. Standardised Mortality Ratios by ICD-10 category (excluding those due to injury and external causes).  
  
 
 
 
Note: Weights are from random effects analysis. SMRs greater than 60 are excluded for presentational purposes. Several studies 
contribute multiple rows of data due to different: outcomes (Graham; Pavarin; Karimina; Randall and Gibson) and time periods 
included (Merrall). 
  
Figure 65. Standardised Mortality Ratios due to injury and external causes 
 
 
Note: Weights are from random effects analysis. SMRs greater than 60 are excluded for presentational purposes. Several studies 
contribute multiple rows of data due to different: outcomes (Nielsen; Graham; Bjornaas; Gibson; Kariminia and Degenhardt) SUD 
groups included (Pavarin); or time periods (Merrall). 
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